Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

Highest Quality | For Research Use Only

Buy Follistatin 344 Slovenia Peptide

Follistatin 344 (FS344) is a naturally occurring protein that functions as an antagonist of myostatin and activin, two members of the transforming growth factor-beta (TGF-β) superfamily. Studies have shown these proteins play a crucial role in the regulation of skeletal muscle mass, where myostatin inhibits muscle growth and differentiation, while activin stimulates the release of follicle-stimulating hormone (FSH) by pituitary cells.

FS344 has garnered significant attention in research due to its potential applications in muscle hypertrophy and atrophy treatment. By binding to and neutralizing myostatin and activin, Slovenia research suggests FS344 can stimulate muscle growth and prevent muscle wasting, making it a promising therapeutic agent for conditions such as muscular dystrophy, sarcopenia, and cachexia.

Showing all 3 results

Potential Benefits of Follistatin 344 Peptide

  • Orthopedic Applications: Research suggests Follistatin has shown potential in inhibiting myostatin, a protein that inhibits muscle growth. This property could have significant implications in orthopedics, potentially helping with muscle regeneration and growth [1].
  • Treatment of Muscular Dystrophy: Studies have demonstrated that follistatin can potentially increase therapeutic benefits in muscular dystrophy. In one study, an antibody against the HA tag present on the follistatin-344 gene was used as a probe [2]. Another study showed that micro-dystrophin and follistatin co-delivery restored muscle function in an aged DMD model [3].
  • Muscle Regeneration: Studies on an engineered follistatin therapeutic showed promise for improving muscle regeneration [4].
  • Increasing Lean Muscle Mass: A study involving mice demonstrated that nanoparticle-mediated hepatic delivery of follistatin mRNA resulted in increased lean muscle mass [5].
  • Localized hypertrophy of skeletal muscle: Research findings indicate that ACE-083, a follistatin-based ligand trap, has demonstrated functional improvement in neuromuscular disease models through the induction of localized hypertrophy of skeletal muscle [6].
  • Becker Muscular Dystrophy Trial: In research, a phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy showed potential benefits [7].

References

[1] https://pubmed.ncbi.nlm.nih.gov/19208403/

[2] https://pubmed.ncbi.nlm.nih.gov/31890729/

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3895965/

[4] https://pubmed.ncbi.nlm.nih.gov/24627466/

[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6276093/

[6] https://pubmed.ncbi.nlm.nih.gov/31388039/

[7] https://pubmed.ncbi.nlm.nih.gov/25322757/

DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://slovenia.direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.